|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-6-15
|
|
pubmed:abstractText |
Currently, hepatitis B immunoglobulins (HBIg) and/or lamivudine have become the main options for prevention of hepatitis B recurrence after liver transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1440-1746
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
872-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20546440-Antiviral Agents,
pubmed-meshheading:20546440-Drug Administration Schedule,
pubmed-meshheading:20546440-Drug Therapy, Combination,
pubmed-meshheading:20546440-Hepatitis B,
pubmed-meshheading:20546440-Humans,
pubmed-meshheading:20546440-Immunoglobulins,
pubmed-meshheading:20546440-Lamivudine,
pubmed-meshheading:20546440-Liver Transplantation,
pubmed-meshheading:20546440-Recurrence,
pubmed-meshheading:20546440-Risk Assessment,
pubmed-meshheading:20546440-Risk Factors,
pubmed-meshheading:20546440-Time Factors,
pubmed-meshheading:20546440-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review.
|
|
pubmed:affiliation |
Beijing Friendship Hospital, Capital Medical University; Municipal Key Laboratory of Beijing for Regulation of Liver Protection and Regeneration. Beijing, China.
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
